8-K: Orthofix Reports First Quarter 2025 Financial Results, Updates Net Sales Guidance

Orthofix Medical Inc. reported its Q1 2025 financial results, updated its full-year net sales guidance, and reaffirmed its full-year 2025 non-GAAP adjusted EBITDA and positive free cash flow guidance.

Summary

• Orthofix Medical Inc. reported first quarter 2025 net sales of $193.6 million, which includes sales from its M6 artificial cervical and lumbar discs.
• Pro forma net sales, excluding sales from its M6 discs, were $189.2 million, representing an increase of 3% on a reported basis and 4% on a pro forma constant currency basis compared to first quarter 2024.
• U.S. Spine Fixation net sales grew by 4% compared to the first quarter of 2024.
• Bone Growth Therapies (BGT) net sales reached $55.1 million, a 5% increase, with BGT Fracture net sales growing by 6% compared to the first quarter of 2024.
• Global Orthopedics net sales were $29.8 million, achieving constant currency growth of 11% and U.S. Orthopedics net sales growth of 10% compared to the first quarter of 2024.
• The company received 510(k) clearance and CE Mark for the TrueLok Elevate Transverse Bone Transport (TBT) System.
• The first quarter 2025 net loss was $(53.1) million on a reported basis.
• Non-GAAP pro forma adjusted EBITDA was $11.4 million, with pro forma adjusted EBITDA margin expanding approximately 200 basis points compared to reported non-GAAP adjusted EBITDA for the first quarter 2024.
• The company is updating its full-year net sales guidance to a range between $808 million to $816 million, excluding sales from the discontinued M6 product lines, representing implied constant currency growth of 5.0% year-over-year at the midpoint of the range.
• Non-GAAP adjusted EBITDA is expected to be $82 million to $86 million.
• Free cash flow is expected to be positive for full-year 2025, excluding the impact of restructuring charges related to the discontinuation of the M6 product lines.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While the company reported a net loss, there are positive aspects such as growth in certain segments, regulatory clearance for a new product, and reaffirmed guidance for adjusted EBITDA and free cash flow. The updated net sales guidance and ongoing commercial channel optimization efforts introduce some uncertainty.

Positives

• Pro forma net sales increased by 4% on a constant currency basis.
• U.S. Spine Fixation net sales showed growth of 4%.
• Bone Growth Therapies (BGT) net sales increased by 5%.
• Global Orthopedics net sales grew by 11% on a constant currency basis.
• The company received regulatory clearance for the TrueLok Elevate Transverse Bone Transport (TBT) System.
• Non-GAAP pro forma adjusted EBITDA margin expanded by approximately 200 basis points.
• The company reaffirmed its full-year 2025 non-GAAP adjusted EBITDA and positive free cash flow guidance.

Negatives

• The company reported a net loss of $(53.1) million for the first quarter of 2025.
• The company updated its full-year net sales guidance from $818 million $826 million to $808 million $816 million.

Risks

• The company's ability to maintain operations to support customers and capitalize on future growth opportunities is a risk.
• Acceptance of surgical products and procedures by surgeons and hospitals poses a risk.
• Development and acceptance of new products or product enhancements is uncertain.
• Clinical and statistical verification of the benefits achieved via the use of the company's products is a risk.
• The company's ability to adequately manage inventory is a risk.
• The company's ability to successfully optimize commercial channels is uncertain.
• Success in defending legal proceedings brought against the company is not guaranteed.
• The company faces risks and uncertainties described in its filings with the SEC.

Future Outlook

Orthofix expects net sales to range between $808 million and $816 million for the full year 2025, excluding sales from the discontinued M6 product lines, representing implied constant currency growth of 5.0% year-over-year at the midpoint of the range; non-GAAP adjusted EBITDA is expected to be $82 million to $86 million; free cash flow is expected to be positive for the full year 2025, excluding the impact of restructuring charges related to the discontinuation of the M6 product lines.

Management Comments

• Massimo Calafiore, President and Chief Executive Officer, stated that the company is continuing to execute the priorities outlined in its three-year plan to transform the business and drive disciplined, profitable growth.
• Mr. Calafiore noted that efforts to optimize the commercial channel resulted in some incremental softness in Biologics and Spine Fixation, but growth is expected to return to historical levels once these efforts are completed.
• Mr. Calafiore mentioned that the company is taking proactive steps to optimize its spine commercial channel and accelerate targeted distributor transitions in a few U.S. territories to maximize growth opportunities and align with its strategic focus.
• Mr. Calafiore stated that the company is focused on three strategic priorities: sharpening commercial execution, implementing projects to improve gross margin, and focusing on disciplined capital allocation, adjusted EBITDA expansion, and positive free cash flow generation.

Industry Context

Orthofix operates in the global medical technology industry, focusing on musculoskeletal pathologies. The company's performance is influenced by factors such as the acceptance of surgical products and procedures, the development of new products, and competition within the industry. The company's focus on spine and orthopedics aligns with the growing demand for these types of medical solutions.

Comparison to Industry Standards

• The document does not provide specific comparisons to industry standards or competitors.
• However, it mentions that Orthofix aims to achieve above-market growth and improve profitability, suggesting that the company is striving to outperform its peers.
• The company's focus on innovation, commercial execution, and operational efficiency are common strategies employed by medical technology companies to gain a competitive edge.

Stakeholder Impact

• Shareholders: The company aims to create long-term value for shareholders through market share gains, adjusted EBITDA expansion, and positive free cash flow generation.
• Customers: The company seeks to deliver exceptional experiences and life-changing solutions to patients around the world.
• Employees: The company is focused on optimizing its commercial channel and implementing strategic initiatives, which may impact employees.
• Suppliers: The company's performance and strategic initiatives may affect its relationships with suppliers.

Next Steps

• The company will continue to focus on sharpening commercial execution to drive deeper market penetration.
• Orthofix will implement projects to improve its gross margin.
• The company will focus on disciplined capital allocation, adjusted EBITDA expansion, and positive free cash flow generation.
• Orthofix plans a full launch of the TrueLok Elevate TBT System in Q3 2025.

Key Dates

Keywords

Orthofix, financial results, net sales, EBITDA, bone growth therapies, spinal implants, orthopedics, guidance, medical technology